Literature DB >> 17146641

[Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].

A Wollenberg1, N Moosmann, J Kroth, V Heinemann, E Klein.   

Abstract

The biological agent cetuximab specifically inhibits the epidermal growth factor receptor (EGFR) function. Cetuximab is licensed for treatment of metastatic colorectal carcinoma, as it enhances the efficacy of cytostatic therapy. Acneiform drug eruptions are common side effects. We report two patients with metastatic colorectal carcinoma, who developed a severe acneiform drug eruption on the face and upper part of the body during the treatment with cetuximab. Triple therapy consisting of systemic isotretinoin, topical nadifloxacin and topical corticosteroid produced rapid improvement with moderate cheilitis the only side effect. We conclude that triple therapy is an effective treatment for patients with severe acneiform drug eruptions caused by cetuximab.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17146641     DOI: 10.1007/s00105-006-1256-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  12 in total

1.  Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy.

Authors:  R Gutzmer; T Werfel; R Mao; A Kapp; J Elsner
Journal:  Br J Dermatol       Date:  2005-10       Impact factor: 9.302

2.  [Cutaneous side effects of EGF-receptor inhibition and their management].

Authors:  R Gutzmer; T Werfel; A Kapp; J Elsner
Journal:  Hautarzt       Date:  2006-06       Impact factor: 0.751

3.  Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes.

Authors:  Koji Murata; Kazunari Sugita; Miwa Kobayashi; Kenji Kabashima; Yoshiki Tokura
Journal:  J Dermatol Sci       Date:  2006-01-23       Impact factor: 4.563

Review 4.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

Authors:  Z Fan; H Masui; I Altas; J Mendelsohn
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

6.  Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.

Authors:  K J Busam; P Capodieci; R Motzer; T Kiehn; D Phelan; A C Halpern
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

7.  Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Authors:  Neelam T Shah; Mark G Kris; William Pao; Leslie B Tyson; Barbara M Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

Review 8.  The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Authors:  Siegfried Segaert; Josep Tabernero; Olivier Chosidow; Thomas Dirschka; Joern Elsner; Luca Mancini; Tim Maughan; Jean-Fran Ois Morere; Armando Santoro; Alberto Sobrero; Eric Van Cutsem; Alison Layton
Journal:  J Dtsch Dermatol Ges       Date:  2005-08       Impact factor: 5.584

9.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

Review 10.  Monoclonal antibodies as therapeutic agents for cancer.

Authors:  Marion Harris
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

View more
  5 in total

1.  [Cutaneous side effects of medical tumor therapy].

Authors:  A Degen; M Alter; F Schenck; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 2.  [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Authors:  P A Gerber; B A Buhren; S Kürle; B Homey
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

3.  Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.

Authors:  Peter Arne Gerber; Stephan Meller; Tatiana Eames; Bettina Alexandra Buhren; Holger Schrumpf; Sonja Hetzer; Laura Maximiliane Ehmann; Wilfried Budach; Edwin Bölke; Christiane Matuschek; Andreas Wollenberg; Bernhard Homey
Journal:  Eur J Med Res       Date:  2012-02-23       Impact factor: 2.175

4.  Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach.

Authors:  M Gobbo; G Ottaviani; G Mustacchi; R Di Lenarda; M Biasotto
Journal:  Lasers Med Sci       Date:  2011-11-26       Impact factor: 3.161

5.  [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].

Authors:  L M Ehmann; V Heinemann; A Wollenberg
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.